or Try an Advanced Search...

    Technical Analysis for VRDN - Viridian Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 18.51 -3.79% -0.73
    VRDN closed down 3.79 percent on Thursday, February 6, 2025, on approximately normal volume. It ran into resistance at its 50 day moving average.
    Earnings due: Feb 25
    *** please verify all earnings dates ***
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical VRDN trend table...
    Date Alert Name Type % Chg
    50 DMA Resistance Bearish 0.00%
    Fell Below 20 DMA Bearish 0.00%
    MACD Bearish Centerline Cross Bearish 0.00%
    Fell Below 50 DMA Bearish -3.79%
    20 DMA Support Bullish -3.79%
    Crossed Above 50 DMA Bullish -6.75%
    MACD Bullish Centerline Cross Bullish -6.75%
    Multiple of Ten Bearish Other -6.75%
    20 DMA Support Bullish -4.09%
    Gapped Down Weakness -4.09%
    Older End-of-Day Signals for VRDN ...

       Recent Intraday Alerts

    Alert Time
    20 DMA Support about 13 hours ago
    Down 5% about 14 hours ago
    60 Minute Opening Range Breakdown about 14 hours ago
    Down 3% about 15 hours ago
    Fell Below Previous Day's Low about 15 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    VRDN Chart by TradingView

    Profile

    Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody in development for thyroid eye disease (TED). Viridian is headquartered in Boulder, Colorado, with research and development operations in Waltham, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Diagnostics & Research
    Keywords: Biotechnology Biology Monoclonal Antibody Thyroid Eye Disease

    Is VRDN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jan 8 Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
    Jan 7 Expert Outlook: Viridian Therapeutics Through The Eyes Of 10 Analysts
    Dec 25 Is Viridian Therapeutics, Inc. (NASDAQ:VRDN) Worth US$19.3 Based On Its Intrinsic Value?
    Dec 19 Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade)
    Dec 18 Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation
    Dec 17 Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade)
    Dec 17 Viridian Therapeutics announces THRIVE-2 trial met primary, secondary endpoints
    Dec 16 Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday
    Dec 16 Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen
    Dec 16 Viridian stock soars 25% on Phase 3 data for veligrotug
    See more VRDN news...

    Comments

    Indicators

    Indicator Value
    52 Week High 27.2
    52 Week Low 11.4
    Average Volume 1,390,684
    200-Day Moving Average 17.61
    50-Day Moving Average 19.40
    20-Day Moving Average 18.62
    10-Day Moving Average 19.24
    Average True Range 1.08
    RSI (14) 45.65
    ADX 8.55
    +DI 22.54
    -DI 22.82
    Chandelier Exit (Long, 3 ATRs) 18.35
    Chandelier Exit (Short, 3 ATRs) 19.83
    Upper Bollinger Bands 20.34
    Lower Bollinger Band 16.90
    Percent B (%b) 0.47
    BandWidth 18.48
    MACD Line -0.03
    MACD Signal Line -0.13
    MACD Histogram 0.1001
    Fundamentals Value
    Market Cap 1.47 Billion
    Num Shares 79.2 Million
    EPS -4.59
    Price-to-Earnings (P/E) Ratio -4.03
    Price-to-Sales 4755.39
    Price-to-Book 2.77
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 20.27
    Resistance 3 (R3) 20.38 19.91 19.97
    Resistance 2 (R2) 19.91 19.46 19.85 19.87
    Resistance 1 (R1) 19.21 19.19 18.98 19.10 19.78
    Pivot Point 18.74 18.74 18.62 18.68 18.74
    Support 1 (S1) 18.04 18.29 17.81 17.93 17.24
    Support 2 (S2) 17.57 18.02 17.51 17.15
    Support 3 (S3) 16.87 17.57 17.05
    Support 4 (S4) 16.76